USV is an API and finished-dose manufacturer based in India. It holds 30 active US drug master files and 14 valid CEPs. Its filings concentrate with DAV (Vietnam), CDSCO (India) and ZAMRA (ZM). Its GMP standing is certified by EMA, MHRA (UK) and CDSCO (India), among 6 authorities. Its most recent recorded inspection, by US FDA, closed on 12 September 2025 as VAI. Customs aggregates show $17.3M of exports covering 334 molecules to 50 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| NAVI MUMBAI, India | Not on file |
| HIMACHAL PRADESH, India | Not on file |
| Mumbai, India | Not on file |
| DAMAN, India | Not on file |
| Vadodara, India | 3027308441 |
| Dabhel, India | 3004086192 |
3 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Metformin | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Acitretin | EDQM, US FDA | 3 |
| Glimepiride | EDQM, US FDA | 3 |
| Pioglitazone | SFDA (Saudi Arabia), US FDA | 3 |
| Donepezil | EDQM, US FDA | 2 |
| Repaglinide | EDQM, US FDA | 2 |
| Rivaroxaban | EDQM, US FDA | 2 |
| Ticagrelor | EDQM, US FDA | 2 |
| Zoledronic Acid | EDQM, US FDA | 2 |
| Clopidogrel | EDQM | 1 |
| Dapagliflozin | US FDA | 1 |
| Dolasetron | US FDA | 1 |
| Elagolix | US FDA | 1 |
| Empagliflozin | US FDA | 1 |
| Etelcalcetide | US FDA | 1 |
| Glibenclamide | EDQM | 1 |
| Glipizide | US FDA | 1 |
| Glyburide | US FDA | 1 |
| Icatibant | US FDA | 1 |
| Imiquimod | US FDA | 1 |
| Irbesartan | SFDA (Saudi Arabia) | 1 |
| Naratriptan | US FDA | 1 |
| Nateglinide | US FDA | 1 |
| Octreotide | US FDA | 1 |
| Olopatadine | US FDA | 1 |
| Palonosetron | US FDA | 1 |
| Regadenoson | US FDA | 1 |
| Ropinirole | US FDA | 1 |
| Sugammadex | US FDA | 1 |
| Trimetazidine | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| DAV (Vietnam) | 11 | None |
| CDSCO (India) | 10 | 2 |
| ZAMRA (ZM) | 5 | None |
| ARCSA (EC) | 3 | None |
| US FDA | 3 | 1 |
| INFARMED (PT) | 3 | None |
| EMA | None | 8 |
| MHRA (UK) | None | 4 |
| ANVISA (Brazil) | None | 1 |
| TMDA (TZ) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $12.7M | 35 |
| 2025 | Not reported | $17.3M | 50 |
| 2024 | Not reported | $16.9M | 30 |
| 2023 | Not reported | $13.6M | 30 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. USV comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.